LIVE ONLINE WEBINAR: Advancing Diagnostic Methods and Optimizing Treatment Decisions to Improve Outcomes in CIDP
Event Date
Thursday, December 4, 2025
Location
Virtual Live Event
Event Time
12:30pm - 1:45pm, EST
Completion Time
75 minutes
Specialty
Neonatology, Neurology
Topic(s)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Credit Available
- Physicians — maximum of 1.25 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
Program Overview
5 minutes: Welcome and Introduction
15 minutes: Overcoming Diagnostic Challenges in CIDP
10 minutes: Optimizing Treatment Strategies for CIDP
20 minutes: Reviewing Developments in CIDP Pathophysiology and Emerging Therapies
20 minutes: Highlights and Clinical Implications from AANEM 2025
5 minutes: Summary and Key Takeaways
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Apply the 2021 EAN/PNS diagnostic guidelines to accurately identify both typical and variant forms of CIDP, with an emphasis on learning how to confidently interpret electrodiagnostic findings and distinguish CIDP from possible CIDP
- Recognize the clinical heterogeneity of CIDP and implement strategies to reduce misdiagnosis, underdiagnosis, and diagnostic delays
- Evaluate the benefits and limitations of traditional CIDP treatments (ie, IVIG, SCIG, corticosteroids, plasma exchange) and identify patient-specific factors that influence treatment selection
- Incorporate shared decision-making practices into CIDP management, ensuring that patient priorities, such as minimizing side effects and optimizing QoL, are central to treatment planning
- Summarize current understanding of CIDP pathophysiology, including the role of autoantibodies, complement activation, and T-cell mediated nerve damage
- Appraise recent clinical trial data for novel therapies targeting CIDP pathophysiology and discuss their potential implications for future practice
Faculty
Vera Bril, BSc, FRCPC, MD
Professor of Medicine
Division of Neurology, University of Toronto,
Director of Neurology and Krembil Family Chair in Neurology, University Health Network,
Toronto Western Research Institute, Toronto, Canada
Director of Neurology, Mount Sinai Hospital, NY, USA
Professor Vera Bril is an expert in the diagnosis and management of patients with complex neuromuscular disorders. Her research interests center on the diagnosis and evidence-based treatment of myasthenia gravis, inflammatory polyneuropathies, and diabetic sensorimotor polyneuropathy. Her work has helped set the standards for electrophysiological investigations in the definition and evaluation of the progression of chronic polyneuropathies. Her research has contributed to understanding the role of intravenous immunoglobulin in the treatment of myasthenia gravis and Guillain-Barré syndrome, and the long-term treatment of chronic inflammatory demyelinating polyneuropathy.
Professor Bril has acted as an advisor to Health Canada and the US Food and Drug Administration. She also serves as the Deputy Physician-in-Chief for Economic Affairs for the Department of Medicine at University Health Network and Mount Sinai Hospital and Chair of the Economics Committee. She is part of the Department of Medicine Executive Committee and helps administer this group of 300 physicians.
Jeffrey Allen, MD
Professor
Department of Neurology
University of Minnesota
Minnesota, USA
Professor Jeffrey Allen completed his neurology residency at Tufts University in Massachusetts, followed by a fellowship in neuromuscular medicine at Harvard Medical School. His research focuses on advancing the diagnosis and treatment of inflammatory neuropathies.
Professor Allen is actively involved in several professional organizations, including the Peripheral Nerve Society, the Inflammatory Neuropathy Consortium, the American Academy of Neurology, and the American Association of Neuromuscular & Electrodiagnostic Medicine. He currently serves as Chairman of the Global Medical Advisory Board for the Guillain-Barré syndrome/chronic inflammatory demyelinating polyneuropathy Foundation International™ and as Treasurer of the Peripheral Nerve Society.
Karissa L. Gable, MD
Professor of Medicine
Neuromuscular Medicine Fellowship Director
Neurology medical student clerkship for the School of Medicine
Duke University Medical Center
Durham, NC, USA
Professor Karissa Gable received her medical degree from the University of North Carolina School of Medicine. She completed a residency in adult neurology at Northwestern Memorial Hospital in Chicago and a fellowship in neuromuscular medicine at Harvard Medical School–Massachusetts General Hospital/Brigham and Women's Hospital in Boston. She is a diplomate in neurology, electrodiagnostic medicine, and neuromuscular medicine.
Professor Gable’s research interests lie in autoimmune neuromuscular disease, with a special interest in neuromuscular junction disease and autoimmune neuropathies such as chronic inflammatory demyelinating polyneuropathy, and she has published widely in peer-reviewed journals in this field.
Luis Querol, MD, PhD
Neuromuscular Diseases Unit, Autoimmune Neurology, Neuromuscular Lab
Neurology Department, Hospital de la Santa Creu i Sant Pau
Institut de Recerca Biomèdica Sant Pau, Barcelona, SpainA
Dr Luis Querol completed his PhD in Medicine at the Universidad Autónoma de Barcelona where he identified clinically useful antibodies in autoimmune neuropathies and the first clinically useful marker in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Through his later work, Dr Querol enabled the discovery and validation of several other autoantibodies in this disorder, which are currently implemented in the clinical routine and commercialized under an ISO9001-approved protocol. Dr Querol has participated in the generation of recent diagnostic and therapeutic guidelines of the European Academy of Neurology/Peripheral Nerve Society, in which he was appointed team leader of the biomarker group, and in multiple Steering Committees of clinical trials in antibody-mediated neuropathies.
Dr Querol is the Coordinator and Principal Investigator for the Autoimmune Neurology Program of the European Rare Diseases Network-Neuromuscular Diseases Neuromuscular Sant Pau and Associate Professor in Neurology at the Universitat Autònoma de Barcelona.